Buy GARDASIL® 9 (Slovakian) Online

GARDASIL 9 is a vaccine indicated for the prevention of various diseases caused by specific types of Human Papillomavirus (HPV). The primary target group includes both girls and boys aged 9 through 45 years. It is designed to prevent:

• Cervical, vulvar, vaginal, anal, oropharyngeal, and other head and neck cancers caused by HPV types 16, 18, 31, 33, 45, 52, and 58.
• Genital warts (condyloma acuminata) caused by HPV types 6 and 11.
• Precancerous lesions:
  • Cervical intraepithelial neoplasia (CIN) grades 1, 2, and 3.
  • Vulvar intraepithelial neoplasia (VIN) grades 2 and 3.
  • Vaginal intraepithelial neoplasia (VaIN) grades 2 and 3.
  • Anal intraepithelial neoplasia (AIN) grades 1, 2, and 3.

Important Notes:

• The vaccine is not a treatment for existing HPV infections or lesions.
• Continued screening for cancers is required even after vaccination.

GARDASIL 9 Dosage Information

The standard dosage for GARDASIL 9 is 0.5 mL per dose, administered via intramuscular injection. The vaccine schedule depends on the patient’s age:

• 9 through 14 years:
  • 2-dose schedule at 0 months and 6-12 months.
  • 3-dose schedule at 0, 2, and 6 months (if required).
• 15 through 45 years:
  • 3-dose schedule at 0, 2, and 6 months.

GARDASIL 9 Key Points:

• If the second dose in the 2-dose regimen is administered earlier than 5 months after the first dose, a third dose is required.
• The vaccine should be administered in the deltoid or anterolateral thigh region.
• Patients should be observed for 15 minutes after administration due to the potential for syncope.

GARDASIL 9 Side Effects and Precautions

The most commonly reported side effects are localized to the injection site and include:

• Injection-site pain:
  • 89.9% in women aged 16-26 years.
  • 71.5% in boys aged 9-15 years.
• Injection-site swelling:
  • 40.0% in women aged 16-26 years.
  • 47.8% in boys aged 9-15 years.
• Headache:
  • 14.6% in women aged 16-26 years.
  • 11.4% in boys aged 9-15 years.

GARDASIL 9 Serious Adverse Reactions:

• Syncope: Occasional fainting episodes, sometimes associated with seizure-like activity. Observation is recommended for 15 minutes post-injection.
• Allergic Reactions: Patients with hypersensitivity to yeast or previous doses of GARDASIL® or GARDASIL 9 should not receive the vaccine.

GARDASIL 9 Postmarketing Experience:

• Rare reports of autoimmune hemolytic anemia, Guillain-Barré syndrome, and acute disseminated encephalomyelitis were noted.

GARDASIL 9 Clinical Studies and Real-World Outcomes

In clinical trials, GARDASIL 9 has shown high efficacy in preventing HPV-related diseases. Here are some of the key findings from the clinical studies:

• Girls and Women (16-26 years):
  • 98.2% efficacy in preventing HPV 16- and 18-related CIN 2/3 and adenocarcinoma in situ (AIS).
  • 100% efficacy in preventing HPV 16- or 18-related VIN 2/3 and VaIN 2/3.
• Boys and Men (16-26 years):
  • 90.6% efficacy in preventing HPV 6, 11, 16, and 18-related external genital lesions.
• Extended Efficacy: Follow-up studies indicated 100% efficacy against cervical and genital disease for up to 60 months post-vaccination.

GARDASIL 9 Drug Interactions

While no extensive studies on GARDASIL 9 interactions with other medications have been conducted, caution is advised when co-administering with immunosuppressive therapies, as these can reduce the vaccine’s efficacy.

GARDASIL 9 Use in Specific Populations

• Pregnancy: Data from clinical studies do not suggest an increased risk of birth defects when GARDASIL 9 is administered during pregnancy, but pregnant women should typically defer vaccination.
• Lactation: There is insufficient data to assess the impact of the vaccine on breastfeeding infants, though the benefits of breastfeeding should be weighed against the mother’s need for the vaccine.
• Pediatric Use: Safety and effectiveness are established in individuals 9 years and older. Efficacy in children younger than 9 years is not established.